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Calcium channel blockers, either amlodipine or mibefradil,
ameliorate renal injury in experimental diabetes.
Background. Diabetic nephropathy is associated with in-
creased albuminuria and accumulation of extracellular matrix
proteins within the kidney. Clinical studies have shown some
beneficial effects of calcium channel blockers (CCB) on dia-
betic nephropathy, even though they are generally considered
to be less renoprotective than agents that interrupt the renin
angiotensin system. However, effects of CCBs on renal injury,
and in particular, expression of extracellular matrix proteins
in a model of normotensive diabetic nephropathy, are poorly
characterized.
Methods. Experimental diabetes was induced by injection of
streptozocin in Sprague-Dawley rats. Amlodipine, a CCB which
blocks the L channel, and mibefradil, a CCB blocking the T
as well as the L channels, were given to diabetic rats for six
months. Albumin excretion rate (AER), pathologic injury, and
expression of the extracellular matrix proteins, collagen I, and
fibronectin were assessed.
Results. Increased AER in diabetic rats (13.2 ×/÷1.3 mg/d,
geometric mean ×/÷ tolerance factor) was attenuated by ei-
ther amlodipine (3.2 ×/÷ 1.4 mg/d) or mibefradil (2.6 ×/÷
1.4 mg/d). Increased glomerulosclerosis and tubulointerstitial
injury in diabetic animals were attenuated by amlodipine and
mibefradil. There was increased collagen accumulation in the
kidney of diabetic rats as assessed by picro-sirius red stain-
ing. Gene expression of both collagen I and fibronectin were
also increased in the kidneys from diabetic animals, as assessed
by reverse transcription-polymerase chain reaction (RT-PCR).
These markers of fibrosis were attenuated by treatment with
either amlodipine or mibefradil. Blood pressure in diabetic rats
(136 ± 2 mm Hg) was modestly reduced by amlodipine (126 ±
3 mm Hg) but not by mibefradil treatment (134 ± 3 mm Hg).
Conclusion. Calcium channel blockers attenuated albumin-
uria, pathologic injury, and accumulation of extracellular matrix
proteins in this normotensive model of diabetic nephropathy.
These findings suggest that CCBs may be useful in preventing
pathologic injury in the diabetic kidney.
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Diabetic nephropathy is a leading cause of the develop-
ment of end-stage renal disease (ESRD) and is a major
cause of morbidity and mortality in the western world.
One of the characteristic features of diabetic nephropa-
thy is persistent albuminuria, particularly at the stage
prior to ESRD [1, 2]. Experimental and clinical stud-
ies have suggested that albuminuria alone may be an in-
dependent risk factor for the development of diabetic
nephropathy. Amelioration of albuminuria is one of the
targets in preventing and retarding the progression of di-
abetic nephropathy [3].
Calcium channel blockers (CCBs) are widely used in
the treatment of hypertension and in other forms of car-
diovascular disease, such as stroke. Diabetic patients of-
ten have hypertension and cardiovascular conditions in
which CCBs are indicated, and therefore, it is important
to also have adequate information on their renoprotec-
tive role in this setting. Clinical studies have shown some
beneficial effects of CCBs on diabetic nephropathy [1,
4], even though these agents are in general considered
to be less renoprotective than agents that interrupt the
renin angiotensin system (RAS), such as the angiotensin-
converting enzyme (ACE) inhibitors and angiotensin re-
ceptor antagonists (ARB) [5]. Indeed, in normotensive
diabetic patients, both ACE inhibitors and ARBs have
been shown to be more effective in reducing albuminuria
than CCBs [6, 7].
Hallmarks of pathologic injury in diabetic nephropathy
include glomerulosclerosis and tubulointerstitial fibrosis
[8]. Experimental diabetes in the rat is associated with
accumulation of extracellular matrix proteins, including
collagens and fibronectin, and this phenomenon is con-
sidered to be pivotal in the development of the overt
manifestation of diabetic nephropathy [9]. However, ef-
fects of CCBs on renal injury, particularly on extracellular
matrix protein expression in the model of normotensive
diabetic nephropathy, are poorly characterized.
Calcium antagonists are a heterogeneous group of
drugs, each with a different chemical structure and phar-
macologic profile. There are several types of calcium
channels, including the L channel and the T channel.
Studies have shown that dihydropyridine CCBs such as
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amlodipine blocks the L channel, whereas a newer cal-
cium antagonist, mibefradil, has a unique chemical struc-
ture and blocks the T channel, as well as the L channel
[10]. In the present study, we assessed the effects of
both CCBs, amlodipine and mibefradil, on albuminuria,
pathologic injury, and renal expression of the extracellu-
lar matrix proteins collagen I and fibronectin in experi-
mental diabetes.
METHODS
Animals
Eight-week-old male Sprague-Dawley rats (body
weight 230 to 280 g) were used in this study. The animal
ethics committee of our institute approved the research
protocol. Diabetes was induced by tail vein injection
of strepozotocin (Boehringer-Mannheim, Mannheim,
Germany) at a dose of 55 mg/kg in citrate following
16-hour fasting. Long-acting insulin (Ultralente, Novo
Industries A/S, Copenhagen, Denmark) at a dose of
4 U/day was given to all diabetic animals by subcutaneous
injection to avoid ketonuria and to maintain well-being.
The animals had access ad libitum to water and standard
rat chow (Clark King & Co., Melbourne, Australia).
Drug therapy
Following the induction of diabetes, the animals were
randomly allocated into three groups and treated for 24
weeks: (1) diabetic rats with no treatment (N = 10);
(2) diabetic rats treated with the dihydropyridine cal-
cium channel blocker amlodipine (Pfizer, New York, NY,
USA) at a dose of 20 mg per kg body weight per day
in food admix (D + Amlodipine, N = 11); (3) diabetic
rats treated with the non-dihydropyridine calcium chan-
nel blocker mibefradil (Roche, Basel, Switzerland) at a
dose of 20 mg per kg body weight per day in food admix
(D + Mibefradil, N = 12). In addition, nondiabetic rats
were used as control animals (N = 10).
Systolic blood pressure (SBP) was measured by tail-
cuff plethysmography in conscious, preheated rats [11]
every four weeks, and body weight was measured. In brief,
rats were restrained and warmed with a heat lamp for five
minutes before measurement, then wrapped in a towel
with the tail exposed, allowing access to the tail-cuff. An
occlusive plethysmograph was attached to a pneumatic
pulse transducer (Narco Bio-system, Inc., Houston, TX,
USA). Three measurements were taken over five minutes
and the mean value calculated.
Animals were placed in metabolic cages at week 24
(Iffa Credo, L’Arbresele, France) for collection of urine
over 24 hours for measurement of albumin concentration
by radioimmunoassay as previously described [12]. Blood
samples were collected from the tail veins of conscious
rats before the animals were sacrificed for measurement
of glycated hemoglobin (HbA1c). HbA1c was measured
by a high-performance liquid chromatography method
(Bio-Rad, Richmond, CA, USA) [13].
Kidney collection
At the conclusion of the experiment, animals were
anesthetized by intravenous injection of pentobarbitone
sodium (60 mg/kg body weight, Boehringer Ingelheim,
Artarmon, NSW, Australia). A midline incision of the
abdomen was cut and the right kidney was removed and
weighed. The kidney was bisected and fixed in 10% for-
malin, and processed to paraffin for subsequent histologic
assessment, in situ hybridization, and immunohistochem-
ical studies.
Kidney histopathology
Glomerulosclerosis and tubulointerstitial injury were
performed using semiquantitative scores as described
previously [14]. Kidney sections were stained with hema-
toxylin and eosin and observed under a light microscope
in a masked fashion at a magnification of ×400 using
the Imaging Analysis System (AIS, Imaging Research,
St. Catherines, Ontario, Canada) associated with a video
camera and computer. All glomeruli in each kidney sec-
tion were graded according to the severity of the glomeru-
lar damage: 0, normal; 1, slight glomerular damage, the
mesangial matrix and/or hyalinosis with focal adhesion,
involving <25% of the glomerulus; 2, sclerosis of 25% to
50%; 3, sclerosis of 50% to 75%; 4, sclerosis of >75% of
the glomerulus. The tubulointerstitial area in the cortex
was observed and graded as: 0, normal; 1, the area of in-
terstitial inflammation and fibrosis, tubular atrophy, and
dilation with cast formation involving <25% of the field;
2, lesion area between 25% and 50% of the field; and
3, lesions involving >50% of the field. The indices for
glomerulosclerosis or tubulointerstitial injury were cal-
culated by averaging the grades assigned to all glomeruli
or fields of tubules.
Picro-sirius red staining
To detect collagen accumulation in the kidney, sections
were stained with picro-sirius red [15]. In brief, sections
were dewaxed and incubated with 0.1% picro-sirius red
in aqueous picric acid for one hour. Slides were washed in
tap water and dried, then mounted. Using this method,
collagens stained as red color. Collagen staining in the
kidney sections were graded according to the densities of
the staining: 1, mild staining; 2, intermediate staining; and
3, strong staining. This was performed under a light mi-
croscope in a masked fashion at a magnification of ×400
using the Imaging Analysis System.
Immunohistochemistry
Protein expression of fibronectin was assessed by us-
ing an immunohistochemical approach [16]. In brief,
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Table 1. Sequences of forward and reverse primers and probes of collagen I and fibronectin
Collagen I Fibronectin
Forward primer 5′TGCCGATGTCGCTATCCA-3′ 5′-CATGGCTTTAGGCGAACCA-3′
Reverse primer 5′TCTTGCAGTGATAGGTGATGTTCTG-3′ 5′CATCTACATTCGGCAGGTATGG-3′
Probe 5′-CCTTCCTGCGCCTGA-3′ 5′-CCCCGTCAGGCTTA-3′
sections were dewaxed, and then endogenous peroxidase
was inactivated using 3% hydrogen peroxide (H2O2) in
methanol for 20 minutes. Sections were blocked with
protein blocking agent for 20 minutes. The kidney sec-
tions were incubated with a rabbit polyclonal fibronectin
antibody (Dako, Carpinteria, CA, USA). Biotinylated
horse antirabbit immunoglobulin (Vector Laboratories,
Burlingame, CA, USA) was used as a second antibody,
followed by horseradish peroxidase–conjugated strepta-
vidin. Peroxidase activity was identified by reaction with
3,3′-diaminobenzidine tetrahydrochloride (DAB; Sigma
Chemical Co., St. Louis, MO, USA).
Reverse transcription-polymerase chain reaction
Three micrograms of total RNA extracted from the
frozen cortex of the kidney was used to synthesize cDNA
with the Superscript First Strand synthesis system for re-
verse transcription-polymerase chain reaction (RT-PCR)
(Life Technologies BRL, Grand Island, NY, USA) [17].
Gene expressions of collagen I and fibronectin were ana-
lyzed by real-time quantitative RT-PCR performed with
the TaqMan system based on real-time detection of ac-
cumulated fluorescence (ABI Prism 7700; Perkin-Elmer,
PE Biosystems, Foster City, CA, USA). To control for
variation in the amount of DNA available for PCR in
the different samples, gene expression of the target se-
quence was normalized in relation to the expression of an
endogenous control, 18S ribosomal RNA (rRNA) (18S
rRNA TaqMan Control Reagent kit; ABI Prism 7700,
PE Biosystems). Primers and TaqMan probe for colla-
gen I and fibronectin and the endogenous reference 18S
rRNA were constructed with the help of Primer Express
(ABI Prism 7700). The primers and the probe specific
for these genes are shown in Table 1. The amplification
was performed with the following time course: 50◦C for
2 minutes and 95◦C for 10 minutes and 50 cycles of 94◦C
for 20 seconds and 60◦C for 1 minute. Each sample was
tested in triplicate. Results were expressed as relative to
control kidneys, which were arbitrarily assigned a value
of 1.
In situ hybridization
In situ hybridization for collagen I was performed
using a method previously described [18, 19]. In brief,
the cDNA probe coding for rat collagen I was cloned
into pBluescript KS+ (Stratagene, La Jolla, CA, USA),
linearized with XbaI and an antisense riboprobe was
produced using T7 RNA polymerase. 35S-labeled RNA
probes for collagen I was prepared with transcription
kits (Promega, Madison, WI, USA). Four-micron sections
were incubated with 35S-labeled RNA probes for collagen
I at 60◦C overnight in a 50% formamide humidified incu-
bator. Slides were washed, dehydrated, air-dried, and ex-
posed to BioMaxMR autoradiographic film for five days.
The films were processed and the optical densities were
quantitated by a microcomputer imaging device (MCID
Imaging system, Ontario, Canada) coupled to an IBM
computer. Slides were then dipped in Amersham nuclear
emulsion (Ilford, Mobberley, Cheshire, UK), stored in a
light-free box at room temperature for three weeks. Sec-
tions were brought to room temperature then immersed
in Kodak D19 developer, washed in acetic acid, and fixed
in Ilford Hypan prior to staining with hematoxylin and
eosin for light microscopy.
Statistical analysis
Data were analyzed by analysis of variance (ANOVA)
using Statview SE (Brainpower, Calabasas, CA, USA)
on a Macintosh computer (Cupertino, CA, USA). Com-
parisons of group means were performed by Fisher least
significant difference method. Because AER did not have
a normal distribution, this parameter was analyzed after
logarithmic transformation. Data are shown as mean ±
SEM unless otherwise specified. A P value of less than
0.05 was viewed as statistically significant.
RESULTS
Metabolic parameters
Diabetic animals had reduced weight gain, increased
HbA1c levels, and increased urine volume when com-
pared to nondiabetic control rats (Table 2). However,
these abnormal metabolic parameters were not signifi-
cantly influenced by any of the drug therapies.
SBP
Mean values of serial measurements of SBP from week
four to 24 after treatment are shown in Table 3. Dia-
betic rats had similar blood pressure over the experimen-
tal period as nondiabetic rats. Amlodipine treated rats
had modestly decreased blood pressure when compared
to untreated diabetic rats at weeks four, eight, and 20.
Mibefradil-treated rats had similar blood pressure to un-
treated diabetic animals (Table 3).
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Table 2. Body weight, kidney weight, blood pressure, and HbA1c
(%) data
D + D +
Parameters Control Diabetic Amlodipine Mibefradil
N 10 10 11 12
Body weight g 509 ± 15 378 ± 13a 350 ± 13a 382 ± 111a
Left kidney g 1.44 ± 0.05 2.06 ± 0.13a 1.66 ± 0.13b 1.96 ± 0.11a
Kidney/body 2.83 ± 0.08 5.48 ± 0.31a 4.51 ± 0.34a,b 5.32 ± 0.34a
weight mg/g
Mean SBP 130 ± 5 136 ± 2 126 ± 3a 134 ± 3
mmHg
HbA1c % 4.4 ± 0.5 11.1 ± 0.3a 10.3 ± 0.2a 10.3 + 0.5a
Urine volume 16 ± 3 97 ± 15a 78 ± 12a 113 ± 8a,c
mL/24h
Mean SBP, mean systolic blood pressure of weeks 4 to 24. Left kidney weight
was used to calculate the kidney/body weight ratios.
aP < 0.05 vs. control; bP < 0.05 vs. diabetic; cP < 0.05 vs. D + Amlodipine.
Table 3. Serial measurement of systolic pressure
D + D +
Parameters Control Diabetic Amlodipine Mibefradil
Week 4 115 ± 4 135 ± 5a 112 ± 4b 124 ± 5
Week 8 125 ± 4 128 ± 5 115 ± 6b 138 ± 4
Week 12 131 ± 6 133 ± 5 135 ± 5 139 ± 6
Week 16 129 ± 5 141 ± 6 136 ± 3 142 ± 5
Week 20 132 ± 6 139 ± 6 126 ± 5b 128 ± 5
Week 24 131 ± 3 137 ± 4 131 ± 4 136 ± 4
Mean of 4 to 130 ± 5 136 ± 2 126 ± 3b 134 ± 3
24 weeks
Mean SBP, mean systolic blood pressure of weeks 4 to 24.
aP < 0.05 vs. control at same time point; bP < 0.05 vs. diabetic at same time point.
Albuminuria
AER was significantly increased in diabetic rats when
compared to control rats (Fig. 1). Treatment with both
amlodipine and mibefradil reduced AER in diabetic rats
to a level that was still higher than that observed in control
animals.
Kidney weight
Kidney weight and the ratio of kidney weight to body
weight are shown in Table 2. Diabetic rats had increased
kidney weight and kidney/body weight ratio when com-
pared to control rats. Only amlodipine treatment was
associated with significantly reduced kidney weight and
kidney/body weight ratio compared to untreated diabetic
animals.
Kidney pathology
Diabetic rats had increased glomerulosclerosis
(Fig. 2A) and tubulointerstitial injury (Fig. 2B) when
compared to control rats. Increased glomerulosclerosis
and tubulointerstitial injury in diabetic rats were reduced
by both treatments (Fig. 2).
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Fig. 1. Albumin excretion rate in control, diabetic, and diabetic
animals treated with amlodipine (Diabetic+A) and mibefradil
(Diabetic+M) are expressed as geometric mean ×/÷ tolerance factor.
∗P < 0.05 vs. control; †P < 0.05 vs. diabetic.
Picro-sirius red staining
Weak collagen staining was detected in the tubuloint-
erstitium, around blood vessels, and in glomeruli in con-
trol kidneys (Fig. 3A). There was a marked increase
in collagen staining in the kidneys from diabetic rats
(Figs. 3B and 4). Treatment with amlodipine or mibefradil
was associated with less collagen staining when compared
to untreated diabetic animals (Figs. 3C, D, and 4).
Fibronectin expression
There was a three-fold increase in gene expression
of fibronectin in the diabetic kidney when compared to
control kidney, as assessed by RT-PCR. Elevated renal
fibronectin gene expression was attenuated by both am-
lodipine and mibefradil therapies to a similar degree
(Fig. 5). Positive fibronectin staining, as assessed by im-
munostaining, was detected in the glomeruli, and to a
lesser extent in the tubulointerstitium. Fibronectin im-
munostaining was increased in the kidneys of diabetic an-
imals (Fig. 6). Both amlodipine and mibefradil treatment
attenuated fibronectin protein expression in the kidney
to a similar level as that observed in control kidneys
(Fig. 6).
Collagen I gene expression
There was an increase in collagen I gene expression
in the diabetic kidney when compared to control kid-
ney, as assessed by RT-PCR (Fig. 7). Attenuated collagen
I gene expression was found in the kidneys of diabetic
rats treated with either amlodipine or mibefradil. In situ
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Fig. 2. Indices of glomerulosclerosis (A) and tubulointerstitial injury
(B) in control, diabetic, and diabetic animals treated with amlodip-
ine (Diabetic+A) and mibefradil (Diabetic+M) are shown as mean ±
SEM. ∗P < 0.05 vs. control; †P < 0.05 vs. diabetic.
hybridization studies showed gene expression of collagen
I predominantly in the tubulointerstitium (Fig. 8A). The
increase in gene expression of collagen I was also detected
in the kidneys of diabetic animals by in situ hybridization
(Fig. 8). Both amlodipine and mibefradil treatments at-
tenuated collagen I gene expression, as assessed by in situ
hybridization, in the diabetic kidney (Fig. 8).
DISCUSSION
The findings of the present study have demonstrated
that CCBs, including amlodipine, an L-channel CCB, and
mibefradil, a T- as well as L-channel CCB, attenuate the
development of albuminuria, prevent kidney structural
injury, and reduce the renal production of extracellular
matrix proteins in normotensive diabetic rats. These find-
ings suggest that CCBs may be useful in preventing patho-
logic injury in the diabetic kidney.
Agents that interrupt the RAS, such as ACE inhibitors
and ARBs, have been recommended as first line drug
therapy for diabetic patients with albuminuria [20]. How-
ever, in contrast to the data obtained with RAS blockers,
the effects of CCBs on diabetic patients with albumin-
uria are conflicting. Some clinical studies have found that
CCBs are effective in reducing albuminuria [1, 21], others
have reported neutral effects [22, 23], and indeed others
have demonstrated that CCBs may be deleterious for the
kidney [24]. A lack of consistent findings for CCBs in hu-
man diabetic nephropathy may be related to a number
of factors, including patient selection (type 1 or type 2 di-
abetes), duration of diabetes, the degrees of underlying
renal injury, the presence or absence of hypertension, and
the different pharmacologic profiles of the CCBs used in
the various clinical studies.
In normotensive patients with type 1 diabetes, the ACE
inhibitor perindopril has been shown to be more effec-
tive than the dihydropyridine CCB nifedipine in delay-
ing the progression of diabetic nephropathy and reducing
urinary albumin excretion [6]. In a study of type 2 dia-
betic patients, both valsartan, an ARB, and amlodipine,
a CCB, achieved a similar degree of blood pressure re-
duction, and yet valsartan lowered the albumin excretion
rate more than amlodipine [7]. Indeed, these findings in
patients with type 2 diabetes and microalbuminuria were
also seen in the subgroup with baseline normotension [7].
This suggests that the antiproteinuric effect of valsartan
is partly independent of blood pressure reduction [7].
It is possible that the renal protection conferred by an-
tihypertensive agents relates not only to their action on
systemic blood pressure, but also their actions on the re-
nal microcirculation. Both approaches interrupt the RAS
(ACE inhibitors and ARBs), and CCBs reduce systemic
blood pressure, and this is clearly important for these
agents’ renoprotective properties. However, these agents
have different actions on the renal microcirculation, par-
ticularly on modulating afferent and efferent arteriolar
tone [25, 26]. It has been demonstrated that there is in-
creased intraglomerular pressure in the context of dia-
betes due to afferent arteriolar vasodilatation even in
the absence of systemic hypertension, which then pro-
motes the development of glomerular injury, including
increased albumin excretion and sclerosis [27]. It has been
shown that ACE inhibitors and ARBs elicit preferential
vasodilation of the efferent arteriole [25], thus amelio-
rating glomerular hypertension and therefore conferring
renal protection. It has been demonstrated that voltage-
dependent L channels predominate in the afferent
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Fig. 3. Representative photomicrographs of
picro-sirius red staining in control (A), di-
abetic (B), diabetic rats treated with am-
lodipine (C), and diabetic rats treated with
mibefradil (D). Collagens were stained as red.
Magnification ×100.
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Fig. 4. Grades of picro-sirius acid staining in control, diabetic, and di-
abetic animals treated with amlodipine (Diabetic+A) and mibefradil
(Diabetic+M) are shown as mean ± SEM. ∗P < 0.05 vs. control; †P <
0.05 vs. diabetic.
arteriole but are sparse or functionally silent at the ef-
ferent arteriole [28]. Because traditional CCBs such as
dihydropyridine CCBs act on L-type calcium channels,
this CCB class causes preferential dilation of the afferent
arteriole, with an only modest action on the efferent ar-
teriole [26]. This may result in glomerular hypertension
that could lead to progression of renal disease. This L-
channel activation of certain CCBs could partly explain
the unfavorable renal effects previously reported with
conventional CCBs in renal disease.
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Fig. 5. Gene expression of fibronectin assessed by reverse
transcription-polymerase chain reaction (RT-PCR) in control,
diabetic, and diabetic animals treated with amlodipine (Diabetic+A)
and mibefradil (Diabetic+M) are shown as mean ± SEM. ∗P < 0.05
vs. control; †P < 0.05 vs. diabetic.
However, newer CCBs, such as mibefradil, which also
blocks T-type calcium channels, have been reported to
dilate both afferent and efferent arterioles [29]. The
T-type channel is present on juxtamedullary efferent arte-
rioles as well as afferent arterioles of superficial and jux-
tamedullary nephrons [28]. Indeed, a number of studies
have suggested a critical role for T-type calcium channels
in modulating efferent arteriolar tone [27]. Mibefradil
decreases both afferent and efferent arteriolar resis-
tance in spontaneously hypertensive rats (SHR) [30].
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Fig. 6. Representative photomicrographs of
fibronectin staining in control (A), diabetic
(B), diabetic rats treated with amlodipine (C)
and diabetic rats treated with mibefradil (D).
Positive fibronectin was stained as brown.
Magnification ×100.
Furthermore, this T-type CCB has been shown to reverse
angiotensin II–induced constriction of the efferent arte-
riole in the isolated perfused rat hydronephrotic kidney
model [27]. Based on these recent in vivo and in vitro stud-
ies, the various actions of CCBs on renal protection might
be related to differences in the distribution of voltage-
dependent calcium channels within the renal microvascu-
lature and the pharmacologic properties of various CCBs.
In the present study, both amlodipine, an L-type
channel CCB, and mibefradil, a T- as well as L-type
CCB, attenuated increased albumin excretion in this
normotensive model of diabetic nephropathy. However,
amlodipine modestly reduced systolic pressure, whereas
mibefradil had no significant influence on systolic blood
pressure. Indeed, it is possible that the beneficial ef-
fects of amlodipine may be primarily related to its action
as a blood pressure–lowering agent, whereas mibefradil
conferred renoprotection primarily via its effects on
glomerular arteriolar resistance.
The difference reported for CCBs in experimental re-
nal disease may relate to the different animal models
that have been examined. For example, amlodipine and
mibefradil have been reported to reduce blood pressure
in subtotally nephrectomized rats, yet failed to attenuate
the increased proteinuria and glomerulosclerosis seen in
that model [31]. Furthermore, in a model combining di-
abetes and hypertension, CCBs failed to attenuate albu-
minuria [32]. This lack of effect of CCBs may be due to the
impairment of renal blood flow autoregulation by both
mibefradil and amlodipine, a phenomenon which could
be deleterious in the setting of systemic hypertension be-
cause it would allow direct transmission of the elevated
systemic blood pressure to the glomerular microcircula-
tion [31].
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Fig. 7. Gene expression of collagen I assessed by reverse transcription-
polymerase chain reaction (RT-PCR) in control, diabetic, and dia-
betic animals treated with amlodipine (Diabetic+A) and mibefradil
(Diabetic+M) are shown as mean ± SEM. ∗P < 0.05 vs. control; †P <
0.05 vs. diabetic.
Increased extracellular matrix proteins in the glomeruli
and tubulointerstitium have been considered major hall-
marks of pathologic injury in diabetic nephropathy [3]. In
a previous study, we found increased fibronectin expres-
sion in the diabetic kidney [9]. In the present study, we
confirmed this finding and showed that both amlodipine
and mibefradil reduced the gene and protein expression
of this extracellular matrix protein in the kidneys from
diabetic animals. Collagen I is also considered an impor-
tant extracellular matrix protein, and in the present study,
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Fig. 8. Representative photomicrographs of collagen I gene expression
by in situ hybridization (arrows) in control (A), diabetic (B), diabetic
rats treated with amlodipine (C), and diabetic animals treated with
mibefradil (D). Left panels are black and white, and right panels are
dark field photomicographs.
increased gene expression of this protein was observed
in the diabetic kidney using both RT-PCR and in situ
hybridization techniques. Furthermore, both amlodipine
and mibefradil attenuated collagen I expression. These
findings suggest that CCBs influence the accumulation
of multiple extracellular matrix proteins by reducing the
synthesis of these proteins and that this leads to the pre-
vention of glomerular and tubulointerstitial injury.
CONCLUSION
Both experimental and clinical studies have demon-
strated that prevention of the rise in blood pressure with
evolving diabetic renal disease, regardless of whether
RAS blockers such as ACE inhibitors or ARBs or CCBs
are used, will delay the onset of nephropathy and albu-
minuria. In this regard, CCBs could be used as part of a
multiple drug approach including first line agents such as
an ACE inhibitor or an ARB, to optimize blood pressure
control, as is currently recommended by recent guide-
lines emphasizing aggressive blood pressure lowering in
subjects with diabetes and/or renal disease [33]. How-
ever, once hypertension and advanced nephropathy are
present, CCBs alone may be inappropriate as monother-
apy without an ACEI or ARB. Indeed, CCBs are only in-
dicated for the treatment of hypertension, and no major
role has been established for this class of antihypertensive
agents in normotensive diabetic patients [6, 7].
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